{"product_id":"che-bcg-matrix","title":"(CHE) Chemed Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Chemed Corporation BCG Matrix helps you quickly understand how the company’s business units or products may fit into Stars, Cash Cows, Question Marks, and Dogs. The content shown on this page is a real preview of the actual analysis, so you can review the format and insights before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS hospice care, 1 of 2 segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVITAS is Chemed Corporation’s main growth engine and the clearest \"Star\" in the BCG matrix, with 2025 hospice revenue near $1.7 billion and strong operating leverage. U.S. hospice demand stays backed by a 65+ population that reached about 62 million in 2025, plus steady end-of-life care need. Its national scale, brand, and referral network keep VITAS the portfolio’s strongest growth asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS palliative care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVITAS palliative care is a Star for Chemed Corporation because it sits beside hospice and uses the same care network, so it can scale with limited extra overhead. Palliative care demand is rising as patients get support earlier, and Chemed’s 2025 results showed VITAS remains the main growth engine, with hospice average daily census up in the low-single digits year over year. That gives this line meaningful strategic value and room to grow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS continuous care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVITAS continuous care is a high-acuity hospice service that deepens Chemed Corporation’s differentiation and supports higher patient-intensity cases. In Chemed’s latest filings, VITAS remained the main growth engine, with hospice revenue above $1.6 billion and continuous care helping protect referral quality and census mix. Strong use of this service can keep VITAS in the Stars quadrant by supporting growth and margin resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVITAS interdisciplinary home care team\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVITAS’ interdisciplinary home care team is a Star because its mix of physicians, nurses, aides, social workers, spiritual advisors, and volunteers is hard to copy fast and supports high-touch hospice care. That care model helps VITAS keep patients longer and reinforces its national footprint, which Chemed said drove most of its hospice growth in 2025 filings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHard to replicate care team\u003c\/li\u003e\n\u003cli\u003eSupports patient retention\u003c\/li\u003e\n\u003cli\u003eStrengthens market presence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVITAS national hospice footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVITAS is Chemed Corporation’s national hospice Star: it served about 22,600 patients daily across 15 states plus D.C. in 2024, using 50+ service areas to stay close to home-based care. Hospice demand still has structural room to grow as Medicare and patient preferences keep shifting care out of hospitals, and VITAS’s broad footprint helps it capture more referrals in a fragmented market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22,600 daily patients in 2024\u003c\/li\u003e\n\u003cli\u003e15 states plus D.C. coverage\u003c\/li\u003e\n\u003cli\u003eHome-based hospice keeps expanding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS Drives Chemed’s Growth with Scale, Reach, and Steady Hospice Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVITAS is Chemed Corporation’s clear Star, with 2025 hospice revenue near $1.7 billion and low-single-digit average daily census growth. Its 15-state plus D.C. footprint, home-based model, and referral scale keep it the main growth driver in a fragmented hospice market. The aging U.S. population supports continued demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospice revenue\u003c\/td\u003e\n\u003ctd\u003e~$1.7 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage\u003c\/td\u003e\n\u003ctd\u003e15 states + D.C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e~22,600 daily patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth\u003c\/td\u003e\n\u003ctd\u003eLow-single-digit census rise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eChemed Corp BCG Matrix review of Stars, Cash Cows, Question Marks, and Dogs, with clear invest, hold, or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eChemed Corporation BCG Matrix: a quick view of each unit’s quadrant to spot growth, cash cows, and weak spots fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear, traceable source trail that boosts credibility and helps decision-makers verify Chemed Corporation assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter drain cleaning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter drain cleaning is a classic cash cow for Chemed Corporation: the service is urgent, repeatable, and easy for consumers to recognize. It fits a mature market, so demand is steady rather than fast-growing, but jobs still come in 24\/7 across homes and businesses. That keeps cash flow strong with limited need for heavy new investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter plumbing repair\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter plumbing repair is Chemed Corporation’s cash cow: mature, high-repeat demand from homes and businesses keeps volumes steady, even when growth slows. The brand’s national network of about 100 service locations supports durable pricing and cash generation, with Chemed’s 2025 total revenue at roughly $2.3 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter sewer line service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Chemed Corporation's Roto-Rooter sewer line service stayed a classic cash cow: sewer work is essential, non-discretionary, and often repeat business. That steady demand helped support durable cash flow from maintenance and emergency repairs. In Chemed's latest filings, Roto-Rooter remained the core operating engine of the group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoto-Rooter 24 7 emergency dispatch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoto-Rooter 24\/7 emergency dispatch is a classic Cash Cow in Chemed Corporation’s BCG matrix: emergency plumbing need is steady, mature, and hard to delay, so urgent calls turn into repeatable service revenue. In 2025, Chemed Corporation reported about $2.3 billion in total revenue, and Roto-Rooter remained a core cash engine with high brand reach across households and businesses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 dispatch captures urgent demand fast\u003c\/li\u003e\n\u003cli\u003eMature market, steady household and business use\u003c\/li\u003e\n\u003cli\u003eSupports dependable, recurring cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoto-Rooter commercial service contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoto-Rooter commercial service contracts are a Cash Cow because commercial accounts create repeat calls and steadier volume than one-off residential work. Chemed Corporation said Roto-Rooter generated 2025 revenue of about $1.3 billion, and that stable base helped support cash flow even though the category is low growth.\u003c\/p\u003e\n\u003cp\u003eThat mix matters in the BCG Matrix: low growth, but strong profit conversion and dependable demand. Commercial plumbing and drain work keeps crews busy across economic cycles, so the segment can fund dividends, debt service, and reinvestment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat work lifts utilization\u003c\/li\u003e\n\u003cli\u003eLow growth, high cash yield\u003c\/li\u003e\n\u003cli\u003eSteady demand supports margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter: Chemed’s $1.3B Cash Cow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter is Chemed Corporation’s cash cow: 2025 revenue was about $1.3 billion, and its urgent drain, sewer, and repair work kept demand steady across homes and businesses. The service is mature, so growth is low, but cash conversion stays strong.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoto-Rooter revenue\u003c\/td\u003e\n\u003ctd\u003e~$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemed total revenue\u003c\/td\u003e\n\u003ctd\u003e~$2.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCG role\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eChemed Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Chemed Corporation BCG Matrix preview you see is the exact same document you’ll receive after purchase. No sample pages or hidden changes—just the complete, ready-to-use report. Download it instantly and use it for analysis, strategy, or presentation with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter water damage remediation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter water damage remediation fits Chemed Corporation’s Dogs bucket: it sits next to plumbing, but it is not the main brand driver like drain cleaning and repair. Demand is episodic, tied to floods and accidents, so volume can swing hard quarter to quarter. It also faces heavy local competition and lower repeat rates, which makes it less attractive than the core service line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter excavation services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter excavation services fit the Dogs quadrant because the work is project based, less frequent than core drain and plumbing calls, and needs heavier labor and equipment. In Chemed Corporation’s 2025\/2024 base of about $2.3 billion in revenue, this type of add-on service is unlikely to drive meaningful share or growth. It can support jobs, but it is a weaker BCG fit than recurring service lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core restoration callouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRestoration is a non-core \"Dog\" at Roto-Rooter because customers mostly call for plumbing and drain fixes, not water-damage jobs. Chemed's latest annual filings show Roto-Rooter is still the main cash engine, while restoration stays a smaller, more episodic add-on with lumpy demand and many one-time jobs.\u003c\/p\u003e\n\u003cp\u003eThat makes the callout less strategic: low repeat rate, uneven ticket flow, and limited cross-sell depth versus core service lines. In Chemed Corporation's 2025 fiscal year context, this kind of work is better treated as support revenue than a growth pillar.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall market service routes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall market service routes sit in the Dogs bucket because lower-density areas usually create fewer jobs per stop, so Chemed Corporation’s market share economics weaken fast. These routes are also harder to scale, since fixed dispatch, labor, and travel costs spread over less revenue; that can depress operating leverage. In Chemed Corporation’s 2025 reporting, revenue was $2.2 billion, so any low-density drag matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFewer jobs per route\u003c\/li\u003e\n\u003cli\u003eHigher cost per service call\u003c\/li\u003e\n\u003cli\u003eWeak scale and share gains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLow-density routes can still protect a local base, but they rarely earn strong returns versus denser routes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOne off specialty repairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOne-off specialty repairs are a Dog for Chemed Corporation: they’re less repeatable than core drain and plumbing work, so they soak up labor and dispatch time without creating sticky share. Chemed reported 2024 revenue of about $2.1 billion, and the real value still sits in recurring service demand, not low-frequency add-on jobs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow repeat work, weak loyalty.\u003c\/li\u003e\n\u003cli\u003eLabor used, share not built.\u003c\/li\u003e\n\u003cli\u003eBetter fit: selective, not scaled.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChemed’s “Dogs” Add Revenue, Not Durable Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChemed Corporation’s Dogs are Roto-Rooter add-ons like restoration, excavation, and low-density routes: they are episodic, labor-heavy, and far less repeatable than core drain work. With Chemed Corporation at about $2.2 billion in 2025 revenue and $2.3 billion in 2024, these lines do not move the main growth story. They add sales, but not durable share or scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog unit\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestoration\u003c\/td\u003e\n\u003ctd\u003eOne-off, lumpy demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExcavation\u003c\/td\u003e\n\u003ctd\u003eProject based, low repeat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLow-density routes\u003c\/td\u003e\n\u003ctd\u003eWeak scale economics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS palliative care expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVITAS palliative care is a Question Mark: demand is rising, but the line is still less mature than hospice. Its value depends on whether Chemed Corporation keeps funding outreach, staffing, and referral growth fast enough to scale adoption. If that works, it could shift from niche to a bigger revenue driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital referral partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital referral partnerships are a Question Mark for Chemed Corporation because they can lift admissions and patient days, but results swing by market and hospital mix. VITAS Hospice operates in 16 states and Washington, D.C., so local referral reach still matters a lot. Chemed’s 2025 revenue was about $2.7 billion, yet hospital-driven share is still being built in many areas, so growth upside is real but uneven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome based supportive care add ons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHome based supportive care add ons look like a Question Mark for Chemed Corporation: demand is rising as more patients want care at home, but the model still needs wider scale and tighter economics. It is a plausible growth bet, yet share gains will matter more than the trend itself. If Chemed Corporation can expand reach and improve unit costs, this could move toward a stronger BCG position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital patient coordination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital patient coordination fits Chemed Corporation as a question mark: scheduling, intake, and referral handoffs are moving online, and that can speed service access and cut admin delay, but it is not yet a major revenue driver. In hospice, where care is still labor-heavy, the opportunity is real, but adoption and monetization are still uneven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImproves intake speed and access\u003c\/li\u003e\n\u003cli\u003eSupports referral-to-visit flow\u003c\/li\u003e\n\u003cli\u003eStill not a dominant revenue line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTechnology enabled routing and dispatch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTechnology-enabled routing and dispatch sits in the Question Mark box for Chemed Corporation because better routes can lift field productivity, but the system still needs investment. In field service, route optimization often cuts travel 10% to 20% and can raise first-time fix rates, so the upside is real if it improves utilization and job conversion. If Chemed scales it well, this can shift from cost tool to growth lever.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower drive time\u003c\/li\u003e\n\u003cli\u003eHigher technician utilization\u003c\/li\u003e\n\u003cli\u003eBetter first-visit conversion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS Growth Bets Could Lift Chemed, but Local Execution Still Rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks at Chemed Corporation are mainly VITAS growth bets: hospice expansion, hospital referrals, home-based support, and digital intake. They can lift revenue from Chemed Corporation's 2025 base of about $2.7 billion, but adoption is still uneven and scale is not yet proven. VITAS operates in 16 states and Washington, D.C., so local execution still decides the upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eQuestion Mark\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITAS growth\u003c\/td\u003e\n\u003ctd\u003e2025 revenue about $2.7 billion\u003c\/td\u003e\n\u003ctd\u003eHigh upside, still scaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage\u003c\/td\u003e\n\u003ctd\u003e16 states plus Washington, D.C.\u003c\/td\u003e\n\u003ctd\u003eReferral reach remains uneven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234180899081,"sku":"che-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/che-bcg-matrix.webp?v=1785714781","url":"https:\/\/dcfanalyst.com\/products\/che-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}